Clinical Trial

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-01-04.
Status change: Not Yet Recruiting → Recruiting 2023-11-20
Trial Details
NCT Number NCT05683717
Lead Sponsor TransThera Sciences (Nanjing), Inc.
Conditions B-Cell Malignancies
Enrollment 37 participants
Start Date 2023-03-30
Primary Completion 2026-10-31 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-21